Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Non-alcoholic fatty liver disease (NAFLD) is
usually a silent disease that occurs in a very high proportion
of people with features of the metabolic syndrome,
including overweight, insulin resistance and type 2 diabetes.
Because obesity and type 2 diabetes are now extremely
common in Westernised societies, it is likely that the
prevalence of NAFLD increases markedly in the future.
Although previously it was thought that NAFLD was
harmless, it is now recognised that NAFLD can be a progressive
liver condition that increases risk of cirrhosis, endstage
liver disease and hepatocellular carcinoma. Additionally,
liver fat accumulation causes insulin resistance
and increases risk of type 2 diabetes. Increasing evidence
now shows NAFLD is a risk factor for cardiovascular
disease (CVD). The purpose of this review is to briefly
discuss the pathogenesis of NAFLD, to describe the relationship
between NAFLD and CVD and the mechanisms
linking both conditions and to discuss some of the treatment
options (including lifestyle, nutrition and drugs) that
may influence both NAFLD and risk of CVD.
Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH, cardiovascular disease (CVD, metabolic syndrome, inflammation, non-esterified fatty acids
332-343
Scorletti, E.
5d46801d-a34a-453c-a3f5-86ebb6e20195
Calder, P. C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, C. D.
1370b997-cead-4229-83a7-53301ed2a43c
December 2011
Scorletti, E.
5d46801d-a34a-453c-a3f5-86ebb6e20195
Calder, P. C.
1797e54f-378e-4dcb-80a4-3e30018f07a6
Byrne, C. D.
1370b997-cead-4229-83a7-53301ed2a43c
Scorletti, E., Calder, P. C. and Byrne, C. D.
(2011)
Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments.
Endocrine, 40 (3), .
(doi:10.1007/s12020-011-9530-x).
(PMID:21894514)
Abstract
Non-alcoholic fatty liver disease (NAFLD) is
usually a silent disease that occurs in a very high proportion
of people with features of the metabolic syndrome,
including overweight, insulin resistance and type 2 diabetes.
Because obesity and type 2 diabetes are now extremely
common in Westernised societies, it is likely that the
prevalence of NAFLD increases markedly in the future.
Although previously it was thought that NAFLD was
harmless, it is now recognised that NAFLD can be a progressive
liver condition that increases risk of cirrhosis, endstage
liver disease and hepatocellular carcinoma. Additionally,
liver fat accumulation causes insulin resistance
and increases risk of type 2 diabetes. Increasing evidence
now shows NAFLD is a risk factor for cardiovascular
disease (CVD). The purpose of this review is to briefly
discuss the pathogenesis of NAFLD, to describe the relationship
between NAFLD and CVD and the mechanisms
linking both conditions and to discuss some of the treatment
options (including lifestyle, nutrition and drugs) that
may influence both NAFLD and risk of CVD.
This record has no associated files available for download.
More information
Published date: December 2011
Keywords:
Non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH, cardiovascular disease (CVD, metabolic syndrome, inflammation, non-esterified fatty acids
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 204661
URI: http://eprints.soton.ac.uk/id/eprint/204661
ISSN: 0969-711X
PURE UUID: eee5208c-22e9-4c9a-8ffc-9eafc6d7b495
Catalogue record
Date deposited: 29 Nov 2011 10:25
Last modified: 15 Mar 2024 03:02
Export record
Altmetrics
Contributors
Author:
E. Scorletti
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
